Sygnis AG. (6/6/17). "Press Release: Sygnis AG Announces Management and Supervisory Board Changes. Dr. Heikki Lanckriet Sole CEO". Madrid & Heidelberg.

	Organisation	Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
	Group	2invest (Group)
	Organisation 2	Accellerate Partners – Peter Llewellyn-Davies
	Product	molecular biology
	Product 2	BIOTECH
	Person	Lanckriet, Heikki (Expedeon 201111 CEO + Founder)
	Person 2	Llewellyn-Davies, Peter (Apeiron 201807– CEO before CFO+CBO before Accellerate Partners + Medigene + Wilex)

•Peter Llewellyn-Davies proposed for the supervisory board

•Pilar de la Huerta to resign from the management board and to transition to the supervisory board

SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced changes to the management team and supervisory board. Dr. Heikki Lanckriet (previously Co-CEO) will become sole CEO of SYGNIS AG and will also retain his role as Chief Scientific Officer.

Dr. Cristina Garmendia Mendizábal, Chairwoman of the SYGNIS Supervisory Board, commented: “I would like to congratulate Heikki, who will act as sole CEO of SYGNIS AG from now on. Following his arrival at SYGNIS in 2016, the leadership team has been redefining and actively progressing the SYGNIS’ buy and build strategy, completing two acquisitions and related financings. I am fully convinced that Heikki will continue this strong momentum and lead SYGNIS to sustained growth and profitability.“

Dr. Heikki Lanckriet, CEO of SYGNIS said: “I am excited to serve as CEO of SYGNIS and I look forward with optimism and determination to grow SYGNIS into a major Company in the molecular biology reagents industry.”

The appointment of all members of the SYGNIS Supervisory Board ends at the General Meeting on July 7, 2017. Maria-Jesús Sabatés Mas and Dr. Franz Wilhelm Hopp will not stand for re-election. Pilar de la Huerta and the long-time financial and biotech executive Peter Llewellyn-Davis will be nominated to replace these members. Pilar de la Huerta resigns from her position as member of the management board with effect of the upcoming annual shareholders meeting on July 7, 2017 in order to take advantage of other opportunities in the pharmaceutical industry.

”On behalf of the Supervisory Board, I want to express our deepest gratitude to Pilar for her invaluable contributions to the development of SYGNIS over the past five years. We are grateful that Pilar has accepted the nomination of the Supervisory Board in order to share her wealth of experience with the team as a Supervisory Board member,” Dr. Cristina Garmendia Mendizábal added. “We would also like to warmly thank Dr. Hopp and Ms. Sabatés Mas for their commitment and service and appreciate their advice during this time of rapid development and change for SYGNIS. We are delighted to invite Mr. Llewellyn-Davies to join the Supervisory Board, where he will serve as the future chairperson of the audit committee. His many years of international financial experience, serving companies in both the UK and Germany, as CFO and board member of public listed life sciences companies, will provide SYGNIS essential insight as the company grows its increasingly international operations and moves towards profitability.”

Mr. Llewellyn-Davis is a British-German national with more than 25 years of financial experience, including as CFO of life sciences companies. He is Founder and Managing Partner of Accellerate Partners, which provides strategic as well as hands-on support for managing an exit or expansion strategy. He currently serves as a non-executive director and chairman of the audit committee of Shield Therapeutics, plc, London, UK, which completed an AIM listing in 2016. From 2012 to 2016, he served as CFO and CBO of Medigene AG, supporting that company’s turnaround plan by developing the equity story, outlicensing marketed and legacy products and growing the investor base with new, large international institutional investors. As CFO of Wilex AG (2006-2012), he managed the company’s IPO; he also set up the investor and public relations function and successfully closed several partnering deals and acquisitions. Prior to WILEX, he served as Executive Director of Müller Dairy (UK) Ltd and Executive Director Finance at Süd-Chemie AG. He has a diploma in business administration from the University of London.

For further information, please contact:

SYGNIS AG
Dr. Heikki Lanckriet
CEO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: sygnis@mc-services.eu

About SYGNIS AG: www.sygnis.com

SYGNIS AG specializes in the development and commercialization of proprietary technologies and offers a wide range of commercial products addressing key challenges in molecular biology. With the 2016 acquisition of Expedeon Holdings, Ltd. based in the UK, SYGNIS added a complementary proteomics product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. In addition, SYGNIS acquired the profitable U.S.-based life sciences tools company C.B.S. Scientific in December 2016 to further expand its product offering. The products of SYGNIS Group are sold through a direct sales force and several distribution partners in Europe, the U.S. and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the U.S. as well as sales offices in Asia. The company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###

Madrid, Spain/Heidelberg, Germany
SYGNIS AG, Waldhofer Str. 104, 69123 Heidelberg, Germany, www.sygnis.de, Tel.: + 49-6221- 3540-125, Fax: +49-6221- 3540-127

Record changed: 2023-06-05